TY - JOUR
T1 - Niche specialization and spread of Staphylococcus capitis involved in neonatal sepsis
AU - the International Consortium for Staphylococcus capitis neonatal sepsis
AU - Study Group on Staphylococci and Staphylococcal Infections (ESGS)
AU - Wirth, Thierry
AU - Bergot, Marine
AU - Rasigade, Jean Philippe
AU - Pichon, Bruno
AU - Barbier, Maxime
AU - Martins-Simoes, Patricia
AU - Jacob, Laurent
AU - Pike, Rachel
AU - Tissieres, Pierre
AU - Picaud, Jean Charles
AU - Kearns, Angela
AU - Supply, Philip
AU - Butin, Marine
AU - Laurent, Frédéric
AU - Adamkova, Vaclava
AU - Barkham, Timothy
AU - Becker, Karsten
AU - Bennett, Desiree
AU - Claris, Olivier
AU - Creech, Clarence Buddy
AU - De Lencastre, Herminia
AU - Deighton, Margaret
AU - Denis, Olivier
AU - Ferguson, John
AU - Huang, Yhu Chering
AU - Klingenberg, Claus
AU - Ingebretsen, Andre
AU - Laferrière, Celine
AU - dos Santos, Katia Regina Netto
AU - Schrenzel, Jacques
AU - Spiliopoulou, Iris
AU - Stefani, Stefania
AU - TaekSoo, Kim
AU - Tarkka, Eveliina
AU - Friedrich, Alex
AU - Vandenbroucke-Grauls, Christina
AU - Ussher, James
AU - Vandenesch, Francois
AU - Westblade, Lars
AU - Lindsay, Jodi
AU - Vandenesch, Francois
AU - Larsen, Anders Rhod
AU - Zanger, Philipp
AU - Kahl, Barbara C.
AU - Aymerich, Cristina Prat
PY - 2020/5/1
Y1 - 2020/5/1
N2 - The multidrug-resistant Staphylococcus capitis NRCS-A clone is responsible for sepsis in preterm infants in neonatal intensive care units (NICUs) worldwide. Here, to retrace the spread of this clone and to identify drivers of its specific success, we investigated a representative collection of 250 S. capitis isolates from adults and newborns. Bayesian analyses confirmed the spread of the NRCS-A clone and enabled us to date its emergence in the late 1960s and its expansion during the 1980s, coinciding with the establishment of NICUs and the increasing use of vancomycin in these units, respectively. This dynamic was accompanied by the acquisition of mutations in antimicrobial resistance- and bacteriocin-encoding genes. Furthermore, combined statistical tools and a genome-wide association study convergently point to vancomycin resistance as a major driver of NRCS-A success. We also identified another S. capitis subclade (alpha clade) that emerged independently, showing parallel evolution towards NICU specialization and non-susceptibility to vancomycin, indicating convergent evolution in NICU-associated pathogens. These findings illustrate how the broad use of antibiotics can repeatedly lead initially commensal drug-susceptible bacteria to evolve into multidrug-resistant clones that are able to successfully spread worldwide and become pathogenic for highly vulnerable patients.
AB - The multidrug-resistant Staphylococcus capitis NRCS-A clone is responsible for sepsis in preterm infants in neonatal intensive care units (NICUs) worldwide. Here, to retrace the spread of this clone and to identify drivers of its specific success, we investigated a representative collection of 250 S. capitis isolates from adults and newborns. Bayesian analyses confirmed the spread of the NRCS-A clone and enabled us to date its emergence in the late 1960s and its expansion during the 1980s, coinciding with the establishment of NICUs and the increasing use of vancomycin in these units, respectively. This dynamic was accompanied by the acquisition of mutations in antimicrobial resistance- and bacteriocin-encoding genes. Furthermore, combined statistical tools and a genome-wide association study convergently point to vancomycin resistance as a major driver of NRCS-A success. We also identified another S. capitis subclade (alpha clade) that emerged independently, showing parallel evolution towards NICU specialization and non-susceptibility to vancomycin, indicating convergent evolution in NICU-associated pathogens. These findings illustrate how the broad use of antibiotics can repeatedly lead initially commensal drug-susceptible bacteria to evolve into multidrug-resistant clones that are able to successfully spread worldwide and become pathogenic for highly vulnerable patients.
UR - http://www.scopus.com/inward/record.url?scp=85083982443&partnerID=8YFLogxK
U2 - 10.1038/s41564-020-0676-2
DO - 10.1038/s41564-020-0676-2
M3 - Article
C2 - 32341568
AN - SCOPUS:85083982443
SN - 2058-5276
VL - 5
SP - 735
EP - 745
JO - Nature Microbiology
JF - Nature Microbiology
IS - 5
ER -